MaxCyte (MXCT) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MaxCyte Inc., a leader in cell-engineering platform technologies, has announced a change of its Nominated Adviser and Joint Broker’s name to Panmure Liberum Limited following the merger of Panmure Gordon (UK) Limited and Liberum Capital Limited. This update reflects the company’s continued progress in the cell therapy sector, leveraging its ExPERT platform to support the development and commercialization of advanced cell-based therapies.
For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.